CSIMarket



China Biologic Products Holdings Inc   (CBPO)
Other Ticker:  
 

China Biologic Products Holdings Inc 's Leverage Ratio

CBPO's quarterly Leverage Ratio and Total Liabilities, Equity growth




CBPO Leverage Ratio (Dec 31 2019)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2018)
IV. Quarter
Y / Y Equity Change -3.79 % -3.79 % -3.79 % -3.79 % 177.68 %
Y / Y Total Liabilities Change -43.39 % -43.39 % -43.39 % -43.39 % 36.55 %
Leverage Ratio MRQ 0.09 0.09 0.09 0.09 0.16
Overall Ranking # 162 # 158 # 0 # 0 # 378
Seq. Equity Change 0 % 0 % 0 % -3.79 % 0 %
Seq. Total Liabilities Change 0 % 0 % 0 % -43.39 % 0 %



Leverage Ratio forth quarter 2019 Comment
Due to repayements of liabilities of 0% China Biologic Products Holdings Inc improved Leverage Ratio in forth quarter 2019 to 0.09, a new company low.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2019, 21 other companies have achieved lower Leverage Ratio than China Biologic Products Holdings Inc . While Leverage Ratio total ranking has deteriorated compare to the previous quarter from 158 to 162.

Explain Leverage Ratio?
Who are CBPO Customers?
Leverage Ratio forth quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 22
Healthcare Sector # 74
Overall Market # 162


Leverage Ratio Statistics
High Average Low
0.93 0.4 0.09
(Sep 30 2014)   (Dec 31 2019)




Financial Statements
China Biologic Products Holdings Inc 's Equity $ 1,775 Millions Visit CBPO's Balance sheet
China Biologic Products Holdings Inc 's Total Liabilities $ 163 Millions Visit CBPO's Balance sheet
Source of CBPO's Sales Visit CBPO's Sales by Geography


Cumulative China Biologic Products Holdings Inc 's Leverage Ratio

CBPO's Leverage Ratio for the trailling 12 Months

CBPO Leverage Ratio

(Dec 31 2019)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2018)
IV. Quarter
Y / Y Equity TTM Growth -3.79 % -3.79 % -3.79 % -3.79 % 177.68 %
Y / Y Total Liabilities TTM Growth -43.39 % -43.39 % -43.39 % -43.39 % 36.55 %
Leverage Ratio TTM 0.09 0.11 0.12 0.14 0.16
Total Ranking TTM # 172 # 172 # 0 # 0 # 100
Seq. Equity TTM Growth 0 % 0 % 0 % -3.79 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 0 % -43.39 % 0 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Due to repayements of liabilities of 0% China Biologic Products Holdings Inc decreased Leverage Ratio in the IV. Quarter to 0.09, a new company low.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 15 other companies have achieved lower Leverage Ratio than China Biologic Products Holdings Inc . While total ranking remained unchanged compare to previous quarter at no. 172.

Explain Leverage Ratio?
Who are CBPO Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 56
Within the Market # 172


TTM Leverage Ratio Statistics
High Average Low
0.62 0.28 0.09
(Dec. 30, 2014)   (Dec 31 2018)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2019, within Biotechnology & Pharmaceuticals Industry Leverage RatioDec 31 2019 MRQ Total LiabilitiesDec 31 2019 MRQ Equity
Xenetic Biosciences Inc.  0.25 $ 4.334  Millions$ 17.213  Millions
Assembly Biosciences inc.  0.24 $ 66.690  Millions$ 273.217  Millions
Arcus Biosciences Inc.  0.24 $ 39.268  Millions$ 163.842  Millions
Pharmacyte Biotech Inc.  0.24 $ 1.019  Millions$ 4.319  Millions
Fate Therapeutics Inc.  0.24 $ 57.518  Millions$ 244.756  Millions
Procyon Corp  0.23 $ 0.494  Millions$ 2.136  Millions
Citius Pharmaceuticals Inc.  0.23 $ 4.606  Millions$ 20.377  Millions
Eyenovia inc.  0.21 $ 2.504  Millions$ 11.741  Millions
Anavex Life Sciences Corp.  0.21 $ 5.464  Millions$ 25.960  Millions
Rubius Therapeutics Inc.  0.21 $ 57.179  Millions$ 274.213  Millions
Vir Biotechnology Inc.  0.21 $ 88.129  Millions$ 423.942  Millions
Zai Lab Limited  0.21 $ 60.493  Millions$ 294.660  Millions
Homology Medicines Inc  0.20 $ 52.060  Millions$ 258.507  Millions
Diffusion Pharmaceuticals Inc.  0.20 $ 3.976  Millions$ 20.134  Millions
Fennec Pharmaceuticals Inc.  0.19 $ 2.271  Millions$ 11.875  Millions
Immunitybio inc.  0.19 $ 22.444  Millions$ 120.679  Millions
Atara Biotherapeutics Inc.  0.18 $ 52.161  Millions$ 290.781  Millions
Jounce Therapeutics inc.  0.18 $ 31.289  Millions$ 174.593  Millions
Microbot Medical Inc  0.18 $ 5.586  Millions$ 31.540  Millions
Seagen Inc.  0.18 $ 329.579  Millions$ 1,876.287  Millions
Mymd Pharmaceuticals Inc.  0.16 $ 1.530  Millions$ 9.355  Millions
Eidos Therapeutics Inc   0.16 $ 27.802  Millions$ 171.427  Millions
Rapt Therapeutics Inc.  0.16 $ 11.481  Millions$ 73.121  Millions
Gossamer Bio Inc.  0.16 $ 54.861  Millions$ 352.485  Millions
Nexien Biopharma Inc.  0.14 $ 0.019  Millions$ 0.128  Millions
Crispr Therapeutics Ag  0.14 $ 127.327  Millions$ 939.425  Millions
Cytrx Corporation  0.13 $ 2.050  Millions$ 15.205  Millions
Immunovant Inc.  0.13 $ 14.757  Millions$ 111.862  Millions
Phathom Pharmaceuticals Inc.  0.13 $ 28.588  Millions$ 227.955  Millions
Acceleron Pharma inc  0.12 $ 55.430  Millions$ 449.476  Millions

Date modified: 2022-05-19T12:22:37-04:00

       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

MYTE's Profile

Stock Price

MYTE's Financials

Business Description

Fundamentals

Charts & Quotes

MYTE's News

Suppliers

MYTE's Competitors

Customers & Markets

Economic Indicators

MYTE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071